Results 31 to 40 of about 676 (157)

Solriamfetol Titration & AdministRaTion (START) in Patients With Narcolepsy

Clinical Therapeutics, 2022
Solriamfetol, a dopamine/norepinephrine reuptake inhibitor, is approved (in the United States and European Union) to treat excessive daytime sleepiness (EDS) in adults with narcolepsy (75-150 mg/d) or obstructive sleep apnea (OSA) (37.5-150 mg/d). This study characterized real-world titration strategies for patients with narcolepsy (with or without ...
Michael J, Thorpy, Danielle, Hyman, Gregory S, Parks, Abby, Chen, Catherine, Foley, Beth, Baldys, Diane, Ito, Haramandeep, Singh   +7 more
openaire   +2 more sources

Retrospective cohort study of hypersomnias of central origin from two Australian tertiary sleep disorders services

Internal Medicine Journal, Volume 53, Issue 10, Page 1783-1789, October 2023., 2023
Abstract Background Hypersomnias of central origin (HOCO) are diverse in origin and symptomatology and remain poorly described in an Australian population. We hypothesised that the rate of human leukocyte antigen (HLA) DQB1*0602 positivity in the Australian cohort would be comparable to international registries.
Lachlan Stranks, Claire M. Ellender, Keith Wong, Haider Naqvi, Ron Grunstein, Brendon J. Yee, Sheila Sivam   +6 more
wiley   +1 more source

Is obstructive sleep apnea a circadian rhythm disorder?

Journal of Sleep Research, Volume 32, Issue 4, August 2023., 2023
Summary Obstructive sleep apnea is the most common sleep‐related breathing disorder worldwide and remains underdiagnosed. Its multiple associated comorbidities contribute to a decreased quality of life and work performance as well as an increased risk of death.
Julija Šmon, Eva Kočar, Tadeja Pintar, Leja Dolenc‐Grošelj, Damjana Rozman   +4 more
wiley   +1 more source

1269 Off-Label Use of Solriamfetol In Idiopathic Hypersomnia [PDF]

Sleep, 2020
Abstract Introduction Solriamfetol is a new daily dopamine and norepinephrine reuptake inhibitor indicated for improving daytime wakefulness in adults with obstructive sleep apnea (OSA) and narcolepsy. It was FDA-approved on 3/20/2019.
Talha Memon, Tammy Wong
openaire   +1 more source

P003 Randomised, placebo-controlled study of solriamfetol for excessive daytime sleepiness in narcolepsy types 1/2 [PDF]

, 2020
n/
Black, Jed, Carter, Lawrence P, Chen, Dan, Corser, Bruce C, Dauvilliers, Yves, Emsellem, Helene A, Mayer, Geert, Plazzi, Giuseppe, Shapiro, Colin M, Thorpy, Michael J, Wang, Hao   +10 more
core   +1 more source

ERS International Congress, Madrid, 2019: highlights from the Sleep and Clinical Physiology Assembly [PDF]

, 2023
The 2019 European Respiratory Society (ERS) International Congress took place in Madrid, Spain, and served as a platform to find out the latest advances in respiratory diseases research. The research aims are to understand the physiology and consequences
Almendros López, Isaac, Andrianopoulos, Vasileios, Baillieul, Sebastien, Bradicich, Matteo, Crespo, Andrea, Marhuenda, Esther, Marillier, Mathieu, Zafeiris, Louvaris   +7 more
core   +1 more source

Science‐Based Approach to Harmonize Contraception Recommendations in Clinical Trials and Pharmaceutical Labels

Clinical Pharmacology &Therapeutics, Volume 113, Issue 2, Page 226-245, February 2023., 2023
This review presents a European Federation of Pharmaceutical Industries and Association/PreClinical Development Expert Group (EFPIA‐PDEG) topic group consensus on a data‐driven approach to harmonized contraception recommendations for clinical trial protocols and product labeling.
Christopher J. Bowman, Nathalie Becourt‐Lhote, Virginie Boulifard, Rüdiger Cordts, Solange Corriol‐Rohou, Brian Enright, Linda Erkman, Jayne Harris, Andreas Hartmann, Jan Hilpert, Sophie Kervyn, Britta Mattson, LaRonda Morford, Mireille Muller, Marcy Powell, Zhanna Sobol, Rajamuthu Srinivasan, Claudia Stark, Kary E. Thompson, Katie J. Turner, Paul Barrow   +20 more
wiley   +1 more source

Profile of Solriamfetol in the Management of Excessive Daytime Sleepiness Associated with Narcolepsy or Obstructive Sleep Apnea: Focus on Patient Selection and Perspectives

Nature and Science of Sleep, 2021
Vivien C Abad Department of Psychiatry & Behavioral Sciences, Division of Sleep Medicine, Stanford University, Redwood City, CA 94063, USACorrespondence: Vivien C AbadDepartment of Psychiatry & Behavioral Sciences Division of Sleep Medicine ...
Abad VC
doaj  

Narcolepsy: Pathophysiology, Diagnosis, Management, and Future Directions, a Narrative Review. [PDF]

Brain Behav
This visual summary outlines the pathophysiology of narcolepsy, driven by hypocretin loss, and details its clinical diagnosis, current management strategies, and the shift toward future disease‐modifying therapies like orexin agonists and immunomodulation.
Hastings NE, Abdi KE, Bibi F, Aslam B, Nuñez MR, Sherani MTR, Shadmani S, Alam U, Hassan VM, Hoor-E-Ainaa, Imran H, Hanna J, Sadat SH.   +12 more
europepmc   +2 more sources

Excessive Daytime Sleepiness in Obstructive Sleep Apnea Patients Treated With Continuous Positive Airway Pressure: Data From the European Sleep Apnea Database [PDF]

, 2021
Excessive daytime sleepiness (EDS) is a symptom of obstructive sleep apnea (OSA) that resolves under treatment with continuous positive airway pressure (CPAP). In some patients, sleepiness persists despite CPAP treatment. We retrospectively analyzed data
Bailly S., Barbera C. D., Basoglu O. K., Bonsignore M. R., Bouloukaki I., Cibella F., Fanfulla F., Grote L., Hein H., Kvamme J. A., Marrone O., McNicholas W. T., Mihaicuta S., Pataka A., Pepin J. L., Saaresranta T., Trakada G., Verbraecken J.   +17 more
core   +2 more sources